Background Empagliflozin (EMPA) reduces heart failure hospitalization and mortality. The
benefit in terms of ventricular arrhythmia and contractility has not been explored. Objective …

Empagliflozin, a sodium-glucose cotransporter-2 inhibitor, has been recently shown to
improve cardiovascular outcomes in patients who have heart failure with preserved ejection …

Abstract The Sodium Glucose Co-Transporter-2 inhibitor, empagliflozin (EMPA), reduces
mortality and hospitalisation for heart failure following myocardial infarction irrespective of …

Background: Recent clinical trials indicate that sodium–glucose cotransporter 2 (SGLT2)
inhibitors improve cardiovascular outcomes in myocardial infarction (MI) patients, but the …

Background Empagliflozin is a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor
used to lower blood sugar in adults with type 2 diabetes. Empagliflozin also exerts …

Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibition reduces heart failure
hospitalizations in patients with diabetes, irrespective of glycaemic control. We examined the …

Background and aims Sodium–glucose linked cotransporter-2 (SGLT2) inhibitors reduce the
likelihood of hospitalization for heart failure and cardiovascular death in both diabetic and …

Aims Empagliflozin, a clinically used oral antidiabetic drug that inhibits the sodium‐
dependent glucose co‐transporter 2, has recently been evaluated for its cardiovascular …

Abstract Aims The EMPA‐REG OUTCOME study showed reduced mortality and
hospitalization due to heart failure (HF) in diabetic patients treated with empagliflozin …

Objectives Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been confirmed to
reduce the rate of rehospitalization for heart failure and cardiovascular death in diabetic …